Cargando…
Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
Bipolar disorder (type 1) is a serious and chronic psychiatric illness that can be difficult to treat. Many bipolar patients have refractory depressive episodes. Racemic ketamine, a glutamate modulator with prominent dissociate and psychedelic properties, has been demonstrated to have rapid acting a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289960/ https://www.ncbi.nlm.nih.gov/pubmed/35859608 http://dx.doi.org/10.3389/fpsyt.2022.867484 |
_version_ | 1784748781810483200 |
---|---|
author | Bennett, Raquel Yavorsky, Christian Bravo, Gary |
author_facet | Bennett, Raquel Yavorsky, Christian Bravo, Gary |
author_sort | Bennett, Raquel |
collection | PubMed |
description | Bipolar disorder (type 1) is a serious and chronic psychiatric illness that can be difficult to treat. Many bipolar patients have refractory depressive episodes. Racemic ketamine, a glutamate modulator with prominent dissociate and psychedelic properties, has been demonstrated to have rapid acting antidepressant and anti-obsessional effects which may be useful for treating the symptoms of bipolar depression. Most of the existing research literature on unipolar and bipolar depression has looked at racemic ketamine in the sub-psychedelic dose range given by infusion as a stand-alone treatment (without concurrent psychotherapy). This article expands on the existing research by articulating three different paradigms for ketamine treatment: biochemical, psychotherapeutic, and psychedelic. The authors use composite clinical vignettes to illustrate different ways of working with ketamine to treat bipolar depression, and discuss a variety of clinical considerations for using ketamine with this population, including route, dose, frequency, chemical mitigators, and adverse events. Note that the conceptual paradigms could be applied to any ketamine treatment, with broad applicability beyond bipolar treatment. |
format | Online Article Text |
id | pubmed-9289960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92899602022-07-19 Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches Bennett, Raquel Yavorsky, Christian Bravo, Gary Front Psychiatry Psychiatry Bipolar disorder (type 1) is a serious and chronic psychiatric illness that can be difficult to treat. Many bipolar patients have refractory depressive episodes. Racemic ketamine, a glutamate modulator with prominent dissociate and psychedelic properties, has been demonstrated to have rapid acting antidepressant and anti-obsessional effects which may be useful for treating the symptoms of bipolar depression. Most of the existing research literature on unipolar and bipolar depression has looked at racemic ketamine in the sub-psychedelic dose range given by infusion as a stand-alone treatment (without concurrent psychotherapy). This article expands on the existing research by articulating three different paradigms for ketamine treatment: biochemical, psychotherapeutic, and psychedelic. The authors use composite clinical vignettes to illustrate different ways of working with ketamine to treat bipolar depression, and discuss a variety of clinical considerations for using ketamine with this population, including route, dose, frequency, chemical mitigators, and adverse events. Note that the conceptual paradigms could be applied to any ketamine treatment, with broad applicability beyond bipolar treatment. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9289960/ /pubmed/35859608 http://dx.doi.org/10.3389/fpsyt.2022.867484 Text en Copyright © 2022 Bennett, Yavorsky and Bravo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Bennett, Raquel Yavorsky, Christian Bravo, Gary Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches |
title | Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches |
title_full | Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches |
title_fullStr | Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches |
title_full_unstemmed | Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches |
title_short | Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches |
title_sort | ketamine for bipolar depression: biochemical, psychotherapeutic, and psychedelic approaches |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289960/ https://www.ncbi.nlm.nih.gov/pubmed/35859608 http://dx.doi.org/10.3389/fpsyt.2022.867484 |
work_keys_str_mv | AT bennettraquel ketamineforbipolardepressionbiochemicalpsychotherapeuticandpsychedelicapproaches AT yavorskychristian ketamineforbipolardepressionbiochemicalpsychotherapeuticandpsychedelicapproaches AT bravogary ketamineforbipolardepressionbiochemicalpsychotherapeuticandpsychedelicapproaches |